المؤلفون: R. Orlova V., E. Kaledina A., A. Malkova M., N. Zhukova V., P. Naymushina A., N. Beliak P., A. Jukova E., A. Sarmatova S., N. Karaseva A., I. Egorova V., K. Teslenko N., A. Tarasov V., Р. Орлова В., Е. Каледина А., А. Малкова М., Н. Жукова В., П. Наймушина А., Н. Беляк П., А. Жукова Е., А. Сарматова С., Н. Карасева А., И. Егорова В., К. Тесленко Н., А. Тарасов В.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2021); 108-113 ; Медицинский Совет; № 9 (2021); 108-113 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: cancer, SARS-CoV-2, COVID-19, immunotherapy, chemotherapy, radiation therapy, злокачественное новообразование, иммунотерапия, химиотерапия, лучевая терапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6253/5667; Du Toit A. Outbreak of a Novel Coronavirus. Nat Rev Microbiol. 2020;18:123. https://doi.org/10.1038/s41579-020-0332-0.; Zhou P., Yang X., Wang X., Hu B., Zhang L., Zhang W. et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat origin. Nature. 2020;579:270–273. https://doi.org/10.1038/s41586-020-2012-7.; Bertuzzi A.F., Marrari A., Gennaro N., Cariboni U., Ciccarelli M., Giordano L. et al. Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy. Cancers (Basel). 2020;12(9):2352. https://doi.org/10.3390/cancers12092352.; Wang Q., Berger N.A., Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2021;7(2):220–227. https://doi.org/10.1001/jamaoncol.2020.6178.; Liang W., Guan W., Chen R., Wang W., Li J., Xu K. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. https://doi.org/10.1016/S1470-2045(20)30096-6.; Giannakoulis V.G., Papoutsi E., Siempos I.I. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob Oncol. 2020;6:799–808. https://doi.org/10.1200/GO.20.00225.; Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. https://doi.org/10.1038/s41586-020-2521-4.; Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://doi.org/10.1136/bmj.m1985.; Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R. et al. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907– 1918. https://doi.org/10.1016/S0140-6736(20)31187-9.; Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A. et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020;10(7):935–941. https://doi.org/10.1158/2159-8290.CD-20-0516.; Lunski M.J., Burton J., Tawagi K., Maslov D., Simenson V., Barr D. et al. Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana. Cancer. 2021;127(2):266– 274. https://doi.org/10.1002/cncr.33243.; Derosa L., Melenotte C., Griscelli F., Gachot B., Marabelle A., Kroemer G., Zitvogel L. The immuno-oncological challenge of COVID-19. Nat Cancer. 2020;1:946–964. Available at: https://www.nature.com/articles/s43018-020-00122-3?error=cookies_not_supported&code=66955eff-548b-4bb7-8885-e78f30bb5078.; Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618– 631. https://doi.org/10.1038/nrc2444.; Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G. et al. “Re-educating” tumor-associated macrophages by targeting NF κB. J Exp Med. 2008;205(6):1261–1268. https://doi.org/10.1084/jem.20080108.; Oh H., Grinberg-Bleyer Y., Liao W., Maloney D., Wang P., Wu Z., Ghosh S. An NF κB transcription-factor-dependent lineage-specific transcriptional program promotes regulatory T cell identity and function. Immunity. 2017;47(3):450–465. https://doi.org/10.1016/j.immuni.2017.08.010.; Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10(6);783–791. https://doi.org/10.1158/2159-8290.CD-20-0422.; Siu K.L., Chan C.P., Kok K.H., Chiu-Yat Woo P., Jin D.Y. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol. 2014;11:141–149. https://doi.org/10.1038/cmi.2013.61.; Versteeg G.A., Bredenbeek P.J., van den Worm S.H., Spaan W.J. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology. 2007;361(1):18–26. https://doi.org/10.1016/j.virol.2007.01.020.; Sun L., Xing Y., Chen X., Zheng Y., Yang Y., Nichols D.B. et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One. 2012;7(2):e30802. https://doi.org/10.1371/journal.pone.0030802.; Narayanan K., Huang C., Lokugamage K., Kamitani W., Ikegami T., Tseng C.T.K., Makino S. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008;82(9):4471–4479. https://doi.org/10.1128/JVI.02472-07.; Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol. 2009;83(13):6689–6705. https://doi.org/10.1128/JVI.02220-08.; Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. https://doi.org/10.1093/cid/ciaa248.; Xie J., Fan H.W., Li T.S., Qiu Z.F., Han Y. Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients. Chinese Academy of Medical Science. 2006;28(2):253–255. Available at: https://pubmed.ncbi.nlm.nih.gov/16733915/.; Li T., Qiu Z., Zhang L., Han Y., He W., Liu Z. et al. Significant Changes of Peripheral T Lymphocyte Subsets in Patients with Severe Acute Respiratory Syndrome. The Journal of Infectious Diseases. 2004;189(4):648– 651. https://doi.org/10.1086/381535.; Wong R.S., Wu A., To K.F., Lee N., Lam C.W., Wong C.K. et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326:1358–1362. https://doi.org/10.1136/bmj.326.7403.1358.; Cui W., Fan Y., Wu W., Zhang F., Wang J.Y., Ni A.P. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clinical infectious diseases. 2003;37(6):857–859. https://doi.org/10.1086/378587.; Zheng H.Y., Zhang M., Yang C.X., Zhang N., Wang X.C., Yang X.P. et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17:541–543. https://doi.org/10.1038/s41423-020-0401-3.; Gu J., Gong E., Zhang B., Zheng J., Gao Z., Zhong Y. et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–424. https://doi.org/10.1084/jem.20050828.; Cheung C.Y., Poon L.L., Ng I.H., Luk W., Sia S.F., Wu M.H. et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol. 2005;79(12):7819–7826. https://doi.org/10.1128/JVI.79.12.7819-7826.2005.; Yilla M., Harcourt B.H., Hickman C.J., McGrew M., Tamin A., Goldsmith C.S. et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus research. 2005;107(1):93–101. https://doi.org/10.1016/j.virusres.2004.09.004.; Tseng C.T.K., Perrone L.A., Zhu H., Makino S., Peters C.J. Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol. 2005;174(12):7977–7985. https://doi.org/10.4049/jimmunol.174.12.7977.; Law H.K., Cheung C.Y., Ng H.Y., Sia S.F., Chan Y.O., Luk W. et al. Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–2374. https://doi.org/10.1182/blood-2004-10-4166.; Tavakkoli M., Wilkins C.R., Mones J.V., Mauro M.J. A novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer. Front Oncol. 2019;9:295. https://doi.org/10.3389/fonc.2019.00295.; Clift A.K., Coupland C.A., Keogh R.H., Diaz-Ordaz K., Williamson E., Harrison E.M. et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371:m3731. https://doi.org/10.1136/bmj.m3731.; Yekedüz E., Utkan G., Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020;141:92–104. https://doi.org/10.1016/j.ejca.2020.09.028.; Lee L.Y., Cazier J.B., Starkey T., Turnbull C.D., Team U.C.C.M.P., Kerr R. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241): 1919–1926. https://doi.org/10.1016/S0140-6736(20)31173-9.; Tini G., Sarocchi M., Tocci G., Arboscello E., Ghigliotti G., Novo G. et al. Arterial hypertension in cancer: the elephant in the room. Int J Cardiol. 2019;281:133–139. https://doi.org/10.1016/j.ijcard.2019.01.082.; Jee J., Foote M., Lumish M., Stonestrom A., Wills B., Narendra V. et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol. 2020;38(30):3538–3546. https://doi.org/10.1200/JCO.20.01307.; Pinato D., Zambelli A., Aguilar-Company J., Bower M., Sng C., Salazar R. et al. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. Cancer Discov. 2020;10(10):1465–1474. https://doi.org/10.1158/2159-8290.CD-20-0773.; Curigliano G., Banerjee S., Cervantes A., Garassino M., Garrido P., Girard N. et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320–1335. https://doi.org/10.1016/j.annonc.2020.07.010.; Weisberg E., Parent A., Yang P., Sattler M., Liu Q., Liu Q. et al. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020;37:167. https://doi.org/10.1007/s11095-020-02851-7.; Luo J., Rizvi H., Egger J.V., Preeshagul I.R., Wolchok J.D., Hellmann M.D. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020;10(8):1121–1128. https://doi.org/10.1158/2159-8290.CD-20-0596.; Vardhana S.A., Wolchok J.D. The many faces of the anti-COVID immune response. J Exp Med. 2020;217(6):e20200678. https://doi.org/10.1084/jem.20200678.; Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914–922. https://doi.org/10.1016/S1470-2045(20)30314-4.; Robilotti E.V., Babady N.E., Mead P.A., Rolling T., Perez-Johnston R., Bernardes M. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–1223. https://doi.org/10.1038/s41591-020-0979-0.; Vordermark D. Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups. Radiat Oncol. 2020;15:140. https://doi.org/10.1186/s13014-020-01579-3.; Joseph N., Choudhury A. Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19. Clin Oncol. 2020;32(7):420–422. https://doi.org/10.1016/j.clon.2020.04.011.; Wild A., Herman J., Dholakia A., Moningi S., Lu Y., Rosati L. et al. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Int J Radiat Oncol. 2016;94(3):571–579. https://doi.org/10.1016/j.ijrobp.2015.11.026.; https://www.med-sovet.pro/jour/article/view/6253

الاتاحة: https://www.med-sovet.pro/jour/article/view/6253
https://doi.org/10.21518/2079-701X-2021-9-108-113

المؤلفون: A. Tarasov V., K. Davtyan V., S. Martsevich Yu., А. Тарасов В., К. Давтян В., С. Марцевич Ю.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 13, No 1 (2017); 18-24 ; Рациональная Фармакотерапия в Кардиологии; Vol 13, No 1 (2017); 18-24 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2017-13-1

مصطلحات موضوعية: atrial fibrillation, radiofrequency ablation of pulmonary veins, the early postoperative period, verapamil, propafenone, sotalol, PROOF study, фибрилляция предсердий, радиочастотная аблация устья легочных вен, ранний послеоперационный период, верапамил, пропафенон, соталол, исследование ПРУФ

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1408/1427; Kirchhof P., Benussi S., Kotecha D., et al. 2016 Esc Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the ESC. Developed with the special contribution of the EHRA of the ESC. Endorsed by the ESO. Eur Heart J. 2016;37(38):2893-962.; January C.T., Wann S., Alpert J.S., et al. 2014 AHA/ACC/HRS Guidelines for the Management of Pa- tients With Atrial Fibrillation: Executive Summary. J Am Coll Cardiol. 2014;64(21):e1-76.; Diagnostics and management of atrial fibrillation. RSC and RNSA guidelines, 2012. Rossiyskiy Kardi- ologicheskiy Zhurnal. 2013;4(102) suppl 3:6-76. (In Russ.) [Диагностика и лечение фибрилляции предсердий. Рекомендации РКО и ВНОА, 2012. Российский Кардиологический Журнал. 2013; 4(102) приложение 3: 6-76].; Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265-325.; Pappone E., Rosanio S., Oreto G., et al. Circumferential Radiofrequency Ablation of Pulmonary Vein Os- tia A New Anatomic Approach for Curing Atrial Fibrillation Carlo. Circulation. 2000;102:2619-28.; Julio J., Chierchia G.B., Chierchia C., et al. Regular atrial tachycardias following vein isolation for parox- ysmal atrial fibrillation: a comparison between the cryoballoon and radiofrequency techniques. J In- terv Card Electrophysiol. 2015;42:161-9.; Calkins H., Brugada J., Packer D.L., et al. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm. 2007;4(6): 816-61.; Calkins H., Kuck K.H., Cappato R., et al. 2012 HRS/EHRA/ECAS Expert Consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4):528-606.; Tarasov A.V., Davtyan K.V., Martsevich S.Yu., Shatakhtsyan V.S. Prevention of atrial tachyarrhythmia in post-operation period of pulmonary veins ostia catheter isolation in paroxysmal atrial fibrillation. Kar- diovaskulyarnaya Terapiya i Profilaktika. 2016;15(5):43-9. (In Russ.) [Тарасов А.В., Давтян К.В., Мар- цевич С.Ю., Шатахцян В.С. Профилактика предсердных тахиаритмий в послеоперационном пе- риоде катетерной изоляции устьев легочных вен у пациентов с пароксизмальной формой фиб- рилляции предсердий. Кардиоваскулярная Терапия и Профилактика. 2016;15(5):43-9].; Sokolov S.F. Allapinin and modern approaches to the treatment of cardiac arrhythmias. Russkiy Med- itsinskiy Zhurnal. 2012;(4):77. (In Russ.) [Соколов С.Ф. Аллапинин и современные подходы к лечению нарушений ритма сердца. Русский Медицинский Журнал. 2012;(4):77].; Elesin D.A., Romanov A.B., Turov A.N., et al. Radiofrequency ablation of paraxysmal and prolonged persistent atrial fibrillation: one-year follow-up with the use of continuous subcutaneous monitoring. Vestnik Aritmologii. 2011;63:5-11. (In Russ.) [Елесин Д.А., Романов А.Б., Туров А.Н. и др. Ра- диочастотная аблация пароксизмальной и длительно персистирующей форм фибрилляции пред- сердий: 1-летний период наблюдения с помощью непрерывного подкожного мониторирования. Вестник Аритмологии. 2011;63:5-11].; Goldenberg G.R., Burd D., Lodzinski P., et al. Antiarrhythmic therapy as an adjuvant to promote post pulmonary vein isolation success - a meta-analysis. J Interv Card Electrophysiol. 2016;21:98-109.; Turco P, De Simone A., La Rocca V., et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing Clin Electrophysiol. 2007;30:S112-5.; Wu G., Jiang H., Huang C., et al. Effects of early postoperative antiarrhythmic drugs on atrial fibril- lation recurrence in the circumferential ablation of pulmonary vein. Chin J Canliol. 2008;36:7.; Darcner S., Chen X., Hansen J., et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind,radiomized, placebo-controlled study (AMIO- CAT trial). Eur Heart J. 2014;35:3356-64.; Kaitani K., Inoue K., Kobori A., et al. EAST-AF trial investigators. Efficacy of antiarrhythmic drugs short- term use after catheter ablation for atrial fibrillation (EAST-EF) trial. Eur Heart J. 2016;37(7);610-8.; https://www.rpcardio.com/jour/article/view/1408

الاتاحة: https://www.rpcardio.com/jour/article/view/1408
https://doi.org/10.20996/1819-6446-2017-13-1-18-24

المؤلفون: M. Leonova V., M. Demidova A., A. Tarasov V., Y. Belousov V., М. Леонова В., М. Демидова А., А. Тарасов В., Ю. Белоусов Б.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 1, No 2 (2005); 4-8 ; Рациональная Фармакотерапия в Кардиологии; Vol 1, No 2 (2005); 4-8 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2005-1-2

مصطلحات موضوعية: arterial hypertension, spirapril, endothelial function, nephroprotection, lipids, glucose metabolism, артериальная гипертензия, спираприл, эндотелиальная функция, нефропротекция, липиды, метаболизм глюкозы

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/346/365; Леонова М.В., Белоусов Ю.Б., Белоусов Д.Ю. и др. Результаты фармакоэпидемиологического исследования больных артериальной гипертонией в России. Качественная клиническая практика, 2004;№1:17-27; Карпов Ю.А., Деев А.Д. Российское исследование эффективности и переносимости Квадроприла® (спираприла) у больных с мягкой и умеренной артериальной гипертонией (КВАДРИГА – КВАД- Роприл И Гипертония Артериальная). Сердце 2002;2(3):1-3.; Шальнова С.А., Марцевич С.Ю., Деев А.Д. и др. Артериальная гипертония в России: исследование ПРОЛОГ как способ доказательства возможностей современной терапии. Рациональная фармакотерапия в кардиологии, 2005;1:4-8.; Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр), М, 2004; Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Noninvasive detection of endothelial dysfunction on children and adults on risk of atherosclerosis. Lancet,1992;340:1111-1115.; Мясоедова Н.В., Леонова М.В. Изучение качества жизни у больных артериальной гипертонией и влияние гипотензивной терапии. Качество жизни. Медицина, 2003;2:48-52.; https://www.rpcardio.com/jour/article/view/346

الاتاحة: https://www.rpcardio.com/jour/article/view/346
https://doi.org/10.20996/1819-6446-2005-1-2-4-8